These findings highlight the MIF–CD74 axis as an important mechanism of MO and DC immunosuppression in metastatic melanoma, and provide a rationale for further evaluation of CDR-based peptides as therapeutic agents able to restore MOs and DCs’ antitumor functions in metastatic melanoma. The gene discussed is CD74; the disease is metastatic melanoma.